BridgeMD
18F-DPA714 PET-MRI study to improve preoperative localisation of the epileptic focus to be resected in drug-resistant partial epilepsy.
EU CTIS ID: 2024-517638-16-00
What this study is testing
To evaluate the contribution of 18F-DPA-714 PET imaging in locating the seizure zone in patients aged 12 and over with drug-resistant partial epilepsy who are candidates for surgery during their phase 2 work-up.
- Human Pharmacology (Phase I)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- FOR PATIENTS: Patients with drug-resistant epilepsy (whose epilepsy epilepsy persists after two types of well-conducted treatment).
- FOR PATIENTS: Male or female .
- FOR PATIENTS: Age : ≥ 12 years
- FOR PATIENTS: Patients with drug-resistant partial epilepsy who have undergone a pre-surgical assessment or phase 1 , the results of which necessitate the use of a SEEG
- FOR HEALTHY VOLUNTEER: Healthy volunteers (i.e. no chronic and/or progressive general pathology)
- FOR HEALTHY VOLUNTEER: Male or female
You likely can't join if
- FOR PATIENTS: Any contraindication to MRI.
- FOR PATIENTS: Pregnant or lactating women, or those not using effective contraception.
- FOR PATIENTS: Lying position impossible to maintain for long periods.
- FOR PATIENTS: Treatment with benzodiazepines such as flunitrazepam, triazolam, diazepam, which may have a moderate affinity for TSPO, be prohibited and must be discontinued at least 15 days before inclusion in the study. Clonazepam, lorazepam, zolpidem, and zopiclone, which have a very low affinity for TSPO, will be tolerated tolerated like other GABA A receptor-modulating antiepileptics.
- FOR PATIENTS: Patients already included in another therapeutic trial using radioactivity.
- FOR HEALTHY VOLUNTEER: Any contraindication to MRI
See the full eligibility criteria
- FOR PATIENTS: Patients with drug-resistant epilepsy (whose epilepsy epilepsy persists after two types of well-conducted treatment).
- FOR PATIENTS: Male or female .
- FOR PATIENTS: Age : ≥ 12 years
- FOR PATIENTS: Patients with drug-resistant partial epilepsy who have undergone a pre-surgical assessment or phase 1 , the results of which necessitate the use of a SEEG
- FOR HEALTHY VOLUNTEER: Healthy volunteers (i.e. no chronic and/or progressive general pathology)
- FOR HEALTHY VOLUNTEER: Male or female
- FOR HEALTHY VOLUNTEER: Age: ≥ 18 years and up to 55 years
- FOR HEALTHY VOLUNTEER: Social security
- FOR PATIENTS: Any contraindication to MRI.
- FOR PATIENTS: Pregnant or lactating women, or those not using effective contraception.
- FOR PATIENTS: Lying position impossible to maintain for long periods.
- FOR PATIENTS: Treatment with benzodiazepines such as flunitrazepam, triazolam, diazepam, which may have a moderate affinity for TSPO, be prohibited and must be discontinued at least 15 days before inclusion in the study. Clonazepam, lorazepam, zolpidem, and zopiclone, which have a very low affinity for TSPO, will be tolerated tolerated like other GABA A receptor-modulating antiepileptics.
- FOR PATIENTS: Patients already included in another therapeutic trial using radioactivity.
- FOR HEALTHY VOLUNTEER: Any contraindication to MRI
- FOR HEALTHY VOLUNTEER: Women who are pregnant, lactating or not using an effective method of contraception
- FOR HEALTHY VOLUNTEER: Lying position impossible to maintain for long periods
- FOR HEALTHY VOLUNTEER: Subject excluded from a medical research protocol.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 0-17 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.